Introduction {#sec1-0269881109349835}
============

The selective serotonin reuptake inhibitor (SSRI) class of antidepressants has had a substantial impact on the treatment of depression since its introduction in the mid-1980s. Escitalopram is an SSRI that is the most selective serotonin-specific antidepressant marketed to date ([@bibr55-0269881109349835]). Escitalopram is the *S*-enantiomer of the racemate citalopram. The efficacy of citalopram as an antidepressant is almost entirely due to the activity of escitalopram; the *S*-enantiomer is approximately 150 times more potent as a reuptake inhibitor than *R*-citalopram in vitro ([@bibr40-0269881109349835]). The mode of action of escitalopram also differs from *R*-citalopram in that it displays a unique interaction with the human serotonin reuptake transporter (SERT) and there is evidence to suggest that it has a self-potentiating effect on the SERT, which is mediated by an allosteric binding site that is distinct from the primary, high-affinity binding site on the SERT ([@bibr79-0269881109349835]).

There is a growing trend to develop drugs that comprise a single enantiomer, as opposed to a mixture of enantiomers. This trend has largely been prompted by the need to develop drugs with improved tolerability profiles, and it is supported by recommendations issued by the Food and Drug Administration (FDA) and the European Medicines Agency for the development of chiral drugs ([@bibr34-0269881109349835]; Committee for Proprietary Medical Products, 1993). Although the racemic nature of drugs has been recognized for many years, it was frequently assumed that only one enantiomer was pharmacologically active; the other enantiomer was considered inactive, or was assumed merely to contribute to the side-effect profile of the drug ([@bibr2-0269881109349835]; [@bibr107-0269881109349835]). However, extensive research has shown that two enantiomers can behave synergistically or antagonistically. Consequently, drugs that are racemates should be considered to be a mixture of potentially different drugs, with potentially different therapeutic and adverse properties ([@bibr20-0269881109349835]; [@bibr65-0269881109349835]); for example, the β-blocker labetalol comprises four different stereoisomer combinations, which can have markedly different physiological effects ([@bibr12-0269881109349835]). Single enantiomer drugs, such as escitalopram, can, therefore, potentially offer a number of distinct benefits, specifically with respect to inter-patient pharmacokinetic and pharmacodynamic variability, as well as reducing toxicity arising from the presence of the therapeutically redundant enantiomers ([@bibr57-0269881109349835]) and improving therapeutic efficacy.

In Europe, escitalopram is currently approved for use in major depressive disorder (MDD), panic disorder, social anxiety disorder, generalized anxiety disorder and obsessive compulsive disorder ([@bibr4-0269881109349835]). Prior to approval of escitalopram in 2002 for the treatment of MDD in the USA, the FDA conducted an extensive review of its clinical efficacy and tolerability data and concluded that escitalopram did not have notable efficacy or tolerability advantages over other marketed antidepressants ([@bibr35-0269881109349835]). However, there have been many studies conducted since that time. This qualitative review of the literature sought to examine the more recent clinical literature and assess whether there is evidence of a clinical advantage for escitalopram over either citalopram or other frequently used antidepressants.

Methods {#sec2-0269881109349835}
=======

Searches were conducted using PubMed and EMBASE. With PubMed, several independent searches were performed. The keyword 'escitalopram' was used in combination with 'placebo', 'citalopram', 'sertraline', 'paroxetine', 'fluoxetine', 'duloxetine' and 'venlafaxine' in separate searches. All searches were limited to trials in adults, clinical trial and English language. Searches were limited to the title/abstract fields. The four searches were then cross-referenced to avoid duplication. For the EMBASE search, the keyword 'escitalopram' was used alone and the search limited to English language and clinical trials. All retrieved titles were then cross-referenced with the searches from PubMed to avoid duplication. No date limits were applied to any of the searches; however, the searches were completed in January 2009 and do not, therefore, include studies published after this date. Published congress abstracts or posters were not included. Abstracts of the retrieved studies were reviewed independently by both authors for inclusion in the analysis and any discrepancies resolved by discussion. Of the retrieved studies, only those pertaining to depression or MDD were selected. All articles were reviewed. Clinical trials were limited to randomized controlled trials (RCTs). Open-label, community-based or naturalistic studies were not included in the analysis; however, findings of the analysis are discussed in the context of the results from these studies and pharmaco-economic studies. Data were extracted for trial design, participant characteristics and outcomes according to the criteria for RCTs as detailed in the Consolidated Standards of Reporting Trials ([@bibr19-0269881109349835]) and the Critical Appraisal Skills Programme ([@bibr72-0269881109349835]).

Results {#sec3-0269881109349835}
=======

The search identified over 250 citations, of which 21 RCTs and 18 pooled studies or meta-analyses in MDD were identified as being suitable for inclusion. The design and outcomes of the RCTs are summarized in Table 1 (available online). A summary of the findings from the published meta-analyses are shown in Table 2 (available online).

Assessment of escitalopram efficacy {#sec4-0269881109349835}
-----------------------------------

### Studies comparing escitalopram with placebo {#sec5-0269881109349835}

A large number of studies have compared escitalopram with placebo, either with or without an active comparator (i.e. citalopram, duloxetine or fluoxetine), and their results largely show a benefit of treatment with escitalopram ([@bibr10-0269881109349835]; [@bibr13-0269881109349835]; [@bibr42-0269881109349835]; [@bibr59-0269881109349835]; [@bibr74-0269881109349835]; [@bibr80-0269881109349835]; [@bibr103-0269881109349835]). In five out of seven studies, escitalopram was significantly better than placebo with respect to all measures of depression (Montgomery-Åsberg depression rating scale (MADRS), Hamilton rating scale for depression (HAM-D) and clinical global impression (CGI) scales) ([@bibr13-0269881109349835]; [@bibr59-0269881109349835]; [@bibr74-0269881109349835]; [@bibr80-0269881109349835]; [@bibr103-0269881109349835]).

Meta-analyses and pooled analyses are important complementary strategies that can be used to compare different therapeutic options ([@bibr97-0269881109349835]). The analyses of [@bibr100-0269881109349835], [@bibr61-0269881109349835], [@bibr58-0269881109349835] and [@bibr37-0269881109349835] all showed a statistically significant improvement in MADRS score with escitalopram compared with placebo after the first week of treatment. In patients who responded after two weeks of treatment, and continued treatment for the entire eight weeks, 63% were in remission at the end of the study ([@bibr100-0269881109349835]). Similarly, an analysis by [@bibr16-0269881109349835] revealed that escitalopram was superior to placebo (and bupropion). A further two analyses explored the impact of disease severity on the efficacy of escitalopram compared with placebo; findings were contradictory, with one analysis reporting a greater difference between escitalopram and placebo in patients who were severely depressed at baseline ([@bibr53-0269881109349835]), and the other demonstrating superiority of escitalopram (10 mg) over placebo in moderately depressed patients, and superiority of escitalopram (20 mg) over placebo in severely depressed patients ([@bibr6-0269881109349835]). More recently, the meta-analysis by [@bibr46-0269881109349835] showed a significant between treatment effect of 2.3 MADRS points, representing a significant clinical benefit favouring escitalopram versus placebo in MDD.

In the analysis by [@bibr91-0269881109349835], which reviewed the efficacy of escitalopram compared with both placebo and citalopram by analysing both published and unpublished data, the authors challenge the efficacy findings with escitalopram, citing potential methodological flaws in the studies that could account for the differences between escitalopram and both placebo and citalopram. It is worth noting that this early analysis included only a small proportion of the studies comparing the efficacy of escitalopram with that of citalopram that have been published to date. Subsequent to the publication of the analysis by [@bibr91-0269881109349835], a total of four clinical studies ([@bibr18-0269881109349835]; [@bibr57-0269881109349835]; [@bibr70-0269881109349835]; [@bibr109-0269881109349835]) and five pooled analyses ([@bibr29-0269881109349835]; [@bibr52-0269881109349835]; [@bibr51-0269881109349835]; [@bibr56-0269881109349835]; [@bibr61-0269881109349835]) were published, and these provide further evidence to support the efficacy findings reported for escitalopram compared with citalopram.

### Studies comparing escitalopram with citalopram {#sec6-0269881109349835}

A total of five randomized, double-blind studies have directly compared the efficacy of escitalopram (10--20 mg) with that of citalopram (10--40 mg) in more than 1700 patients. The mean change in MADRS score was significantly greater in patients receiving escitalopram than citalopram at both six ([@bibr109-0269881109349835]) and eight weeks ([@bibr13-0269881109349835]; [@bibr18-0269881109349835]; [@bibr57-0269881109349835]; [@bibr70-0269881109349835]). At 24 weeks, however, there was no significant difference in efficacy between citalopram and escitalopram ([@bibr18-0269881109349835]). In the two placebo-controlled, randomized, double-blind studies in which citalopram was used as an active comparator, analysis of time to separation from placebo showed that escitalopram (10--20 mg) resulted in a statistically significant separation from placebo on all rating scales during weeks 1--2, compared with weeks 6--8 for citalopram (20--40 mg) ([@bibr13-0269881109349835]; [@bibr57-0269881109349835]). This suggests that treatment with escitalopram is associated with earlier relief of depressive symptoms compared with citalopram ([@bibr44-0269881109349835]), which is in keeping with findings from preclinical studies ([@bibr84-0269881109349835]; [@bibr86-0269881109349835]). Only a single study reported an increased prevalence of adverse events with citalopram compared with escitalopram ([@bibr109-0269881109349835]); in all other studies, both treatments were found to be equally safe and well tolerated ([@bibr13-0269881109349835]; [@bibr18-0269881109349835]; [@bibr57-0269881109349835]; [@bibr70-0269881109349835]).

Furthermore, three pooled analyses have compared the efficacy of escitalopram with that of citalopram ([@bibr36-0269881109349835]; [@bibr56-0269881109349835]; [@bibr61-0269881109349835]). In these three studies, escitalopram was superior to citalopram with respect to MADRS score ([@bibr36-0269881109349835]; [@bibr56-0269881109349835]; [@bibr61-0269881109349835]). In the study by [@bibr56-0269881109349835], for example, the mean decrease from baseline in MADRS total score in the results of the pooled studies was greater after eight weeks of treatment in escitalopram-treated patients than in those treated with citalopram, even in a subpopulation of severely ill patients (i.e. those with MADRS score of ≥30). Two early pooled analyses of the initial registration trials showed a faster onset and superior efficacy of escitalopram compared with citalopram ([@bibr36-0269881109349835]; [@bibr56-0269881109349835]). Data on speed of onset need to be viewed cautiously because statistical separation is partly dependent on subject numbers ([@bibr94-0269881109349835]).

Recently, [@bibr46-0269881109349835] demonstrated a significant treatment difference in terms of MADRS, remission rates and responder rates favouring escitalopram versus SSRIs in people with MDD, and the main source of these differences were due to differences between escitalopram versus citalopram. Similar findings were obtained in an analysis of patients with severe depression at baseline.

Positive effects of escitalopram on measures of sleep have been shown in a study by Lader and colleagues in comparison with citalopram ([@bibr52-0269881109349835]). Patients with MDD associated with sleep problems, defined as MADRS item 4 score ≥4, were treated with escitalopram, citalopram or placebo. Patients treated with escitalopram showed improvement in mean MADRS item 4 score at weeks 4, 6 and 8 compared with patients treated with both placebo (*p* \< 0.05) and citalopram (*p* \< 0.01). Furthermore, few patients (\<6%) reported sleep-related, treatment-emergent adverse events, such as daytime somnolence and/or insomnia ([@bibr52-0269881109349835]).

### Studies comparing escitalopram with other selective serotonin reuptake inhibitors {#sec7-0269881109349835}

The efficacy of escitalopram in MDD has been compared with that of paroxetine in two randomized, double-blind studies. Escitalopram elicited a statistically significant improvement in MADRS, HAM-D and CGI-severity (CGI-S) scores following 8 weeks of treatment ([@bibr11-0269881109349835]) and, in a subgroup of severely depressed patients, significant improvement in MADRS score was detected at 27 weeks ([@bibr3-0269881109349835]). Furthermore, not only was there an increase in the rate of treatment discontinuations owing to adverse events in paroxetine compared with escitalopram-treated patients ([@bibr3-0269881109349835]; [@bibr11-0269881109349835]), but significantly more patients in the paroxetine group withdrew from the study owing to lack of efficacy ([@bibr3-0269881109349835]).

Only two randomized, double-blind studies compared the efficacy of escitalopram with that of fluoxetine and these studies have reported conflicting results. The study by [@bibr64-0269881109349835] in Chinese patients showed no significant difference between the two treatments at 8 weeks, although escitalopram was superior with respect to both the 'depressed mood' and 'work and interests' items of the HAM-D scale. The second study, by [@bibr42-0269881109349835] in elderly patients, suggested that although fluoxetine was significantly less efficacious than both escitalopram and placebo, escitalopram in turn was not superior to placebo. The adverse-event profile of the two antidepressants was similar ([@bibr63-0269881109349835]), but there were a greater number of treatment discontinuations with fluoxetine compared with escitalopram owing to either adverse events or lack of efficacy ([@bibr42-0269881109349835]).

A single study has explored the comparative efficacy of escitalopram and sertraline and found no differences between agents ([@bibr99-0269881109349835]). However, in this study a fixed dose of escitalopram of 10 mg/day, which is the lowest therapeutic dose, was compared with sertraline flexibly dosed across its entire recommended dose range of 50--200 mg/day (mean dose at week 8: 144 mg/day). The similarity in the efficacy of these two antidepressants reported in this clinical study may not, therefore, translate into clinical practice.

### Studies comparing escitalopram with serotonin-noradrenaline reuptake inhibitors {#sec8-0269881109349835}

The efficacy of escitalopram has been directly compared with that of venlafaxine XR in two randomized, double-blind studies, in a total of 484 patients, and found to be very similar ([@bibr7-0269881109349835]; [@bibr69-0269881109349835]), but with some advantage of escitalopram in patients with severe MDD ([@bibr68-0269881109349835]). Three randomized, double-blind studies have compared the efficacy of escitalopram and duloxetine ([@bibr47-0269881109349835]; [@bibr74-0269881109349835]; [@bibr78-0269881109349835]; [@bibr102-0269881109349835]). Two of these revealed that patients treated with escitalopram had greater improvements in MADRS score ([@bibr47-0269881109349835]; [@bibr102-0269881109349835]): one study showed a statistically significantly greater efficacy for escitalopram compared with duloxetine at eight weeks ([@bibr47-0269881109349835]); the other demonstrated that the mean change from baseline to week 8 in MADRS score was significantly greater in escitalopram- versus duloxetine-treated patients ([@bibr102-0269881109349835]). Another study, designed to establish non-inferiority, demonstrated that duloxetine had as fast an onset of efficacy as escitalopram and was associated with similar efficacy over the 8 weeks of the study: 42.6% and 35.2% of patients had a 20% sustained reduction in HAM-D Maier subscale score with duloxetine and escitalopram, respectively (*p* = 0.097). Both treatments were better than placebo (*p* \< 0.001 for duloxetine versus placebo and *p* = 0.008 for escitalopram versus placebo) ([@bibr74-0269881109349835]). However, in a six-month extension of this study, there was no significant difference in efficacy between escitalopram and duloxetine, although escitalopram did have a significantly improved effect on sleep ([@bibr78-0269881109349835]). In a pooled analysis of two clinical studies by Lam and Wade, the incidence of nausea, insomnia, dizziness and vomiting was statistically significantly higher in patients treated with duloxetine compared with those treated with escitalopram; however, the incidence of upper respiratory tract infection was statistically significantly higher in patients treated with escitalopram ([@bibr52-0269881109349835]). Overall, the authors concluded that escitalopram demonstrated superior tolerability, as evidenced by lower overall withdrawal rates as a result of adverse events ([@bibr52-0269881109349835]). These findings mirror those from individual studies comparing escitalopram and duloxetine ([@bibr47-0269881109349835]; [@bibr74-0269881109349835]; [@bibr78-0269881109349835]; [@bibr102-0269881109349835]).

### Meta-analysis of studies comparing escitalopram, selective serotonin reuptake inhibitors and serotonin-noradrenaline reuptake inhibitors {#sec9-0269881109349835}

In addition to the numerous head-to-head trials of escitalopram and individual SSRIs and serotonin-norepinephrine reuptake inhibitors (SNRIs), several meta-analyses were identified that examined the relationships between antidepressants in terms of their efficacy and tolerability. One meta-analysis revealed that escitalopram had superior efficacy compared with other antidepressants (e.g. citalopram, fluoxetine, paroxetine, sertraline and venlafaxine XR), as assessed by MADRS on a series of endpoint comparisons involving change in efficacy scores from baseline, and response and remission rates ([@bibr45-0269881109349835]). This meta-analysis included 10 clinical trials and was designed to detect an overall difference between escitalopram and other antidepressants as a group. It did not draw firm conclusions on the comparative efficacy of escitalopram and any one of the individual antidepressants listed, as the number of studies directly comparing escitalopram with these individual antidepressants was low. Another meta-analysis by [@bibr44-0269881109349835] reported similar findings: the mean change in MADRS score was found to be significantly higher in patients treated with escitalopram after one week of treatment, and this benefit persisted for the duration of time that assessments were made. Interestingly, the CGI-S scores also revealed that escitalopram was associated with a faster onset of action than other antidepressants. An earlier meta-analysis confirmed the superiority of escitalopram versus citalopram with respect to both response and remission rates, but found no difference between escitalopram and venlafaxine XR ([@bibr28-0269881109349835]). This is perhaps not surprising given the small number of patients who received venlafaxine XR in the single study included in this analysis. Meanwhile, a more recent meta-analysis by [@bibr46-0269881109349835], which included 16 studies of escitalopram of eight weeks' duration or longer in the treatment of MDD, revealed that escitalopram was associated with more favourable MADRS scores and remission and responder rates compared with placebo, SSRIs and SNRIs ([Figure 1](#fig1-0269881109349835){ref-type="fig"}), and the results were comparable when the analyses were restricted to patients with severe depression (baseline MADRS ≥30), although the benefit of escitalopram versus SSRIs was largely due to differences between escitalopram versus citalopram. Figure 1.Response and remission rates^a^ following treatment at end of study (A) for all patients and (B) for severely depressed patients (permission pending from [@bibr46-0269881109349835]). ^a^Response (defined as a ≥50% reduction in baseline MADRS total score; LOCF) and remission (defined as MADRS total score ≤12; LOCF) rates. Data are odds ratios with 95% CIs. CI: confidence interval; ESC: escitalopram; LOCF: last observation carried forward; MADRS: Montgomery-Asberg depression rating scale; SNRI: selective norepinephrine reuptake inhibitor; SSRI: selective serotonin reuptake inhibitor.

The recent meta-analysis by [@bibr15-0269881109349835] concluded that there were clinically important differences between antidepressants in terms of efficacy (response rate) and acceptability (patient discontinuation); the conclusions were in favour of escitalopram and sertraline. This independently funded meta-analysis systematically reviewed 117 RCTs and evaluated 12 commonly prescribed antidepressants, including citalopram, escitalopram, duloxetine, fluoxetine, paroxetine, sertraline and venlafaxine, in 25,928 patients with unipolar MDD. The methodology used differed from other meta-analyses, since it incorporated a matrix design to allow multiple treatment comparisons. The meta-analysis did not include outcomes such as side-effects, toxic effects, discontinuation symptoms and social functioning. Mirtazapine, escitalopram, venlafaxine and sertraline were more efficacious than duloxetine, fluoxetine, fluvoxamine, paroxetine and reboxetine. Escitalopram, sertraline, citalopram and bupropion were judged to be more acceptable than the other antidepressants evaluated. Thus, escitalopram and sertraline were established as treatments of choice in depression.

Assessment of escitalopram tolerability and safety {#sec10-0269881109349835}
--------------------------------------------------

In terms of safety and tolerability, data for escitalopram are available from over 4000 patients in double-blind treatment, representing approximately 1000 patient-years of exposure ([@bibr4-0269881109349835]). Overall, the adverse-event profile detailed in published studies and meta-analyses is consistent with the known serotonergic properties of escitalopram. A meta-analysis of safety data from 24 double-blind, active-comparator or placebo-controlled, randomized studies with escitalopram was recently published ([@bibr4-0269881109349835]). The most common adverse events (incidence ≥5%) reported during the first 8 weeks of treatment with escitalopram, which were significantly more frequent than in the placebo group, were nausea, insomnia, fatigue, diarrhoea, dizziness, dry mouth, somnolence and ejaculation failure (Table 3, available online). The majority of these events were mild to moderate in severity ([@bibr4-0269881109349835]).

From weeks 8 to 24, only nasopharyngitis (escitalopram 3.2% vs comparator 2.9%) and headache (escitalopram 2.5% vs comparator 2.6%) had an incidence ≥2% ([@bibr4-0269881109349835]). Importantly, particularly for a treatment used long term in clinical practice, in the heterogeneous patient samples studied, escitalopram was both safe and well tolerated ([@bibr1-0269881109349835]; [@bibr43-0269881109349835]; [@bibr100-0269881109349835]). No new types of adverse events were seen in long-term treatment compared with acute treatment ([@bibr4-0269881109349835]; [@bibr43-0269881109349835]; [@bibr100-0269881109349835]). Furthermore, weight gain, which is frequently cited as reason for non-adherence to long-term SSRI treatment, was not seen after 24 weeks of treatment with escitalopram ([@bibr4-0269881109349835]).

In the same meta-analysis, the safety profile of escitalopram was also compared with other antidepressants, including citalopram, fluoxetine, paroxetine, sertraline and venlafaxine XR. The withdrawal rate at 8 weeks owing to adverse events was significantly lower for escitalopram compared with both paroxetine and venlafaxine XR, and escitalopram resulted in fewer discontinuation signs and symptoms than paroxetine ([@bibr4-0269881109349835]). The latter finding is mirrored by a study that utilized telephone calls reporting symptoms of antidepressant withdrawal received by the UK national medication helpline between October 1997 and March 2005. Of the total of 1753 calls, 39.4% related to paroxetine, whereas 0.9% related to escitalopram. Furthermore, the numbers of calls relating to symptoms of withdrawal were also high with both venlafaxine XR (14.4%) and citalopram (8.0%) compared with escitalopram. However, it is worthwhile noting that the number of calls relating to symptoms of withdrawal is also dependent on the number of prescriptions written, and the same study reported that a much higher number of prescriptions was dispensed for paroxetine (24.3 million), venlafaxine (12.2 million) and citalopram (19.3 million) compared with escitalopram (1.75 million) ([@bibr94-0269881109349835]).

Three randomized, double-blind studies have assessed the safety of escitalopram compared with that of duloxetine, which were not included in the analysis by [@bibr4-0269881109349835]. Duloxetine was associated with an increased incidence of adverse events, particularly insomnia and constipation ([@bibr74-0269881109349835]; [@bibr102-0269881109349835]), as well as significant increases in the incidence of nausea, dry mouth, yawning and vomiting (all *p* \< 0.05) ([@bibr74-0269881109349835]), and in two out of the three studies, these adverse events accounted for an increase in the rate of discontinuation in patients treated with duloxetine compared with those treated with escitalopram ([@bibr47-0269881109349835]; [@bibr102-0269881109349835]). Although, in one study, escitalopram was associated with a higher incidence of treatment-emergent sexual dysfunction at 4 weeks when compared with duloxetine, there was no significant difference at 12 weeks and no difference in the rates of discontinuations due to sexual dysfunction ([@bibr17-0269881109349835]).

Discussion {#sec11-0269881109349835}
==========

Clinical benefits of escitalopram compared with other antidepressants {#sec12-0269881109349835}
---------------------------------------------------------------------

Over the last five years, a large body of evidence has accumulated establishing the clinical efficacy and safety of the *S*-enantiomer, escitalopram compared with other antidepressants (see summary points below). These findings provide further evidence to support the efficacy findings reported for escitalopram compared with citalopram, which had previously been disputed by [@bibr91-0269881109349835]. It should also be noted that during peer-review of our manuscript, a post-hoc pooled analysis of data from two 6-month RCTs was published, which concluded that escitalopram is a good therapeutic option for the long-term treatment of MDD ([@bibr41-0269881109349835]). In addition, an integrative analysis of four double-blind, randomized, clinical trials, that was published during peer review of our manuscript, concluded that escitalopram is at least as effective as the SNRIs (venlafaxine XR and duloxetine), even in severe depression, and was better tolerated ([@bibr50-0269881109349835])

Although only a small number of studies have directly compared escitalopram with paroxetine, fluoxetine and sertraline, these SSRIs have been included in several meta-analyses, which have evaluated the outcome of multiple clinical trials assessing the efficacy and tolerability of antidepressants. The most recent, and perhaps most compelling meta-analysis, by Cipirani et al. (2009), concluded that escitalopram and sertraline might be the best choice of antidepressant when starting treatment of patients with moderate to severe MDD, since they offer the best ratio of efficacy and acceptability. It is noteworthy that escitalopram and citalopram were compared separately in this meta-analysis ([@bibr15-0269881109349835]).

A number of meta-analyses suggest that the SNRI venlafaxine XR is associated with greater remission or response rates in patients with MDD compared with SSRIs ([@bibr73-0269881109349835]; [@bibr76-0269881109349835]; [@bibr89-0269881109349835]; [@bibr96-0269881109349835]; [@bibr98-0269881109349835]). These results have prompted some authors to debate whether dual-action antidepressant drugs that combine both a serotonergic and noradrenergic mechanism of action are more effective in patients with MDD than the SSRIs ([@bibr76-0269881109349835]). The evaluation of the efficacy of escitalopram in comparison with the SNRIs venlafaxine XR and duloxetine may have been limited by the small number of studies directly comparing these agents; however, these studies were performed in a large number of patients (\>1500 patients) and, thus, were sufficiently powered to identify important clinical differences between the treatments ([@bibr15-0269881109349835]).

Summary points for efficacy: efficacy advantage for escitalopram versus citalopram has been demonstrated in five randomized studies ([@bibr13-0269881109349835]; [@bibr18-0269881109349835]; [@bibr57-0269881109349835]; [@bibr70-0269881109349835]; [@bibr109-0269881109349835]) and two pooled analyses of clinical trials ([@bibr36-0269881109349835]; [@bibr56-0269881109349835]);escitalopram may have an efficacy advantage over paroxetine, in terms of significant improvements in MADRS, HAM-D and CGI-S scores and fewer discontinuations owing to lack of efficacy ([@bibr3-0269881109349835]; [@bibr11-0269881109349835]);the efficacy of escitalopram compared with fluoxetine ([@bibr63-0269881109349835]; [@bibr42-0269881109349835]) and sertraline ([@bibr99-0269881109349835]) requires further evaluation;escitalopram and sertraline might be the best choice of antidepressant when starting treatment of patients with moderate to severe MDD ([@bibr15-0269881109349835]);the SNRI venlafaxine XR may be associated with greater remission or response rates in patients with MDD compared with SSRIs ([@bibr76-0269881109349835]; [@bibr89-0269881109349835]; [@bibr73-0269881109349835]; [@bibr96-0269881109349835] [@bibr98-0269881109349835] Burk et al., 2002);escitalopram has comparable efficacy to venlafaxine XR, with a possible slight advantage for escitalopram in patients with severe MDD ([@bibr7-0269881109349835]; [@bibr69-0269881109349835])

Regarding safety and tolerability, escitalopram offers tolerability advantages over duloxetine, paroxetine and venlafaxine XR (see summary points below) and may be preferable to those antidepressants in some patients with MDD.

Summary points for safety: superior tolerability for escitalopram versus duloxetine, particularly for nausea, insomnia, dizziness and vomiting has been demonstrated in three randomized studies ([@bibr47-0269881109349835]; [@bibr74-0269881109349835]; [@bibr102-0269881109349835]) and a pooled analysis of two clinical trials (Lam et al., 2008)escitalopram offers tolerability advantages over paroxetine ([@bibr3-0269881109349835]; [@bibr11-0269881109349835]) and venlafaxine XR ([@bibr7-0269881109349835]; [@bibr69-0269881109349835], 2006);escitalopram is less likely to cause discontinuation symptoms than several other antidepressants ([@bibr3-0269881109349835]; [@bibr7-0269881109349835]; [@bibr11-0269881109349835]; [@bibr42-0269881109349835]; [@bibr47-0269881109349835]; [@bibr69-0269881109349835], 2006; [@bibr93-0269881109349835]; [@bibr102-0269881109349835]);no evidence of emergent risk of suicide with escitalopram ([@bibr4-0269881109349835]; [@bibr77-0269881109349835]);incidence of sexual dysfunction-related adverse events similar to citalopram, but lower than venlafaxine XR and paroxetine ([@bibr4-0269881109349835]).

Why might escitalopram confer clinical advantages to citalopram? {#sec13-0269881109349835}
----------------------------------------------------------------

Careful consideration of a drug's stereochemistry is becoming increasingly important when developing new antidepressants to provide greater insight into the pharmacological subtleties of the agents being prescribed in clinical practice ([@bibr5-0269881109349835]). It can be postulated that the observed clinical benefits of escitalopram compared with citalopram are conferred by the pharmacological and pharmacodynamic properties of the constituent enantiomers. These properties are summarized below.

In addition to overall clinical efficacy in terms of symptom improvement, another potential clinical advantage that escitalopram may confer compared with citalopram is earlier onset of action ([@bibr44-0269881109349835]). Increasing attention has been focused on the requirement for antidepressant medications to have a rapid onset of effect ([@bibr8-0269881109349835]; [@bibr81-0269881109349835]; [@bibr94-0269881109349835]), since this can translate into clinical benefit in terms of symptom control and treatment continuation ([@bibr44-0269881109349835]). Initial clinical results ([@bibr44-0269881109349835]), which were identified in the literature search (Table 1, available online), suggested that escitalopram had a faster onset of action compared with citalopram (see summary points below). It has been suggested that the reduction in serotonergic activity as a result of autoreceptor activation is the rate-limiting step in the clinical response to antidepressants. Therefore, more rapid desensitization of the receptors, as observed with escitalopram, could lead to a faster onset of action ([@bibr30-0269881109349835]).

Summary points for escitalopram versus citalopram: escitalopram (*S*-enantiomer) has improved pharmacological potency as a serotonin reuptake inhibitor in vitro versus the *R*-enantiomer; the *S*-enantiomer has the benefit of allosterically modulating the SERT; (Hyttel et al., 1992)the *R*-enantiomer is metabolized more slowly than the *S*-enantiomer ([@bibr88-0269881109349835]), resulting in approximately two-fold higher plasma concentration of the *R*-enantiomer ([@bibr75-0269881109349835]; [@bibr92-0269881109349835]);*R*-citalopram may have a functional antagonistic effect on escitalopram ([@bibr21-0269881109349835]; [@bibr30-0269881109349835]; [@bibr63-0269881109349835]; [@bibr71-0269881109349835];) with significantly higher occupancy 6 h post-dose with escitalopram (10 mg/day: 82%) compared with citalopram (20 mg/day: 64%) ([@bibr48-0269881109349835]; [@bibr66-0269881109349835]);*R*-citalopram should not be considered an inactive enantiomer: it may have a deleterious influence on the activity of escitalopram through functional antagonism ([@bibr31-0269881109349835]);escitalopram may have a faster onset of action than citalopram ([@bibr83-0269881109349835]; [@bibr85-0269881109349835], [@bibr87-0269881109349835]) as a result of more rapid desensitization of 5-hydroxytryptamine~1A~ subtype autoreceptors, leading to more rapid disinhibition of the serotonergic neurones, and enhanced release of serotonin ([@bibr9-0269881109349835]).

Translating clinical efficacy into 'real-life' benefit {#sec14-0269881109349835}
------------------------------------------------------

The outcomes of naturalistic studies can provide insight into the use of escitalopram in the wide range of patients with MDD seen in clinical practice. While evidence-based medicine is the main platform upon which treatment efficacy is evaluated, it is important that the findings from RCTs translate into real, everyday clinical practice. The patient populations of RCTs are typically homogeneous as they are determined based on the stringent inclusion and exclusion criteria required for regulatory approval of a specific indication; therefore, for a treatment to be clinically relevant, the results from RCTs must apply to the broader population of patients treated in psychiatric and primary care practices. However, although studies conducted under 'real-life' conditions provide valuable insight into the efficacy of the drug in a population that is representative of outpatients suffering from depression, the findings from such studies cannot be included in meta-analyses that determine the overall treatment effect. A number of such naturalistic studies have been conducted with escitalopram and their findings are consistent with those reported in RCTs ([@bibr56-0269881109349835]; [@bibr67-0269881109349835]; [@bibr82-0269881109349835]). In these studies, 8 weeks of treatment with escitalopram was associated with improvements in measures of depression, including MADRS score and CGI-improvement score ([@bibr67-0269881109349835]; [@bibr82-0269881109349835]). These findings were corroborated by a large-scale, uncontrolled open-label study of [@bibr67-0269881109349835], in which over 11,500 patients were treated and 83% showed much or very much improved CGI-I ([@bibr67-0269881109349835]).

The long-term efficacy of escitalopram, in terms of improved symptom severity, has been demonstrated in a number of six- or 12-month open-label studies ([@bibr1-0269881109349835]; [@bibr43-0269881109349835]; [@bibr100-0269881109349835]), in which the majority of patients (72% to 86%) achieved remission (MADRS ≤12). It would, therefore, appear that the mechanistic advantages of escitalopram over citalopram, in terms of increased potency ([@bibr39-0269881109349835]) and its known effect on the SERT through an affinity-modulating allosteric site ([@bibr14-0269881109349835]), translate into clinical benefits in patients with MDD, as demonstrated in the pooled analysis by [@bibr61-0269881109349835], which showed significantly greater mean change from baseline in MADRS with escitalopram versus citalopram (56% vs 41%**,** respectively; *p* = 0.007).

In addition to the requirement for efficacy and safety, it is pertinent that an antidepressant agent is cost-effective. In 2007, the cost of treating depression, including both direct and indirect costs, was estimated at €118 billion per year in Europe ([@bibr53-0269881109349835]). Several pharmaco-economic studies have suggested that escitalopram may be more cost-effective than citalopram ([@bibr22-0269881109349835]; [@bibr27-0269881109349835]; [@bibr32-0269881109349835]; [@bibr36-0269881109349835]; [@bibr39-0269881109349835]; [@bibr90-0269881109349835]; [@bibr105-0269881109349835], b; [@bibr108-0269881109349835]) and duloxetine ([@bibr105-0269881109349835]) and at least as cost-effective as venlafaxine XR ([@bibr23-0269881109349835]; [@bibr27-0269881109349835]; [@bibr33-0269881109349835]; [@bibr51-0269881109349835]; [@bibr62-0269881109349835]; [@bibr90-0269881109349835]). These results suggest that the improved efficacy of escitalopram, both in clinical trials and in 'real life\', translate into improved cost-effectiveness, thereby relieving some of the burden of depression on healthcare authorities and this is supported by Cipriani et al ([@bibr15-0269881109349835]). However, it should be noted that the cost-effective analyses were conducted when venlafaxine XR was under patent and this should be considered when interpreting these data.

Limitations of this literature review {#sec15-0269881109349835}
-------------------------------------

It is important to acknowledge a number of potential limitations of this literature review article, which are common to all review articles of this nature. These include publication bias, i.e. the selective publication of trials with positive results, and differences in study design, including dosing regimens, sample sizes and inclusion criteria ([@bibr25-0269881109349835]; [@bibr24-0269881109349835]; [@bibr28-0269881109349835]).

An important consideration when interpreting these findings is the issue of dose comparability. Ideally, individual studies included in any review, qualitative or quantitative, should involve dosing across the full regulatory-approved dose range for each treatment group. If this is not the case, in order to ensure fair comparability between the two treatment groups, the study should assess the efficacy of minimal doses of drug A with minimal doses of drug B, and high doses should be compared with high doses ([@bibr60-0269881109349835]). The dose of escitalopram used across the studies included in this review ranged from 10 to 20 mg, which is the dose range approved in Europe. All of the included studies comparing escitalopram and citalopram involved comparable doses. However, it should be pointed out that the majority of these comparative studies used fixed doses of escitalopram and citalopram and it is possible that these fixed-dose studies simply used more effective doses of escitalopram than citalopram. Some of the comparative studies with other antidepressants cannot be considered to be dose comparable and this should, therefore, be considered when interpreting their findings; for example, in the study by Montgomery and colleagues, 10--20 mg of escitalopram was compared with 75--150 mg of venlafaxine XR ([@bibr69-0269881109349835]).

In addition, many of the studies included here involved relatively small samples of patients, which may limit interpretation owing to insufficient power to detect reliably the differences between two effective treatments ([@bibr95-0269881109349835], [@bibr95-0269881109349835]). However, the combining of data in meta-analyses helps to overcome this potential limitation.

Finally, although changes in scores on clinical scales such as the MADRS and HAM-D, are well-established measures of clinical efficacy, antidepressants can also be assessed using validated surrogate outcomes, which may be better measures of 'real-life' efficacy, such as remission rates, quality of life, patient-reported outcomes and productivity ([@bibr53-0269881109349835]); for example, the recent study by [@bibr26-0269881109349835], showed that patients treated with escitalopram reported a statistically and clinically significant improvement in quality of life enjoyment and satisfaction using data from eight randomized, eight-week, clinical trials. This review did not assess efficacy in terms of these patient-centred outcomes; however, a number of observational or naturalistic studies were included, and these can be assumed to better capture treatment efficacy in the 'real-life' clinical setting.

Conclusions {#sec16-0269881109349835}
===========

In the recent past it has been thought that there is very little difference in both efficacy and safety between antidepressants currently available. However, there is evidence suggesting that the mechanistic advantages of escitalopram over the *R*-enantiomer and racemic citalopram translate into clinical efficacy benefits, both in the context of clinical studies and the 'real-life' setting. In addition, there is evidence that the onset of treatment response is earlier with the *S*-enantiomer alone.

Evidence for an efficacy advantage over other SSRIs and SNRIs is less robust, but escitalopram does appear to offer some tolerability advantages over several other antidepressants, particularly the SNRIs, venlafaxine XR and duloxetine. Escitalopram is, therefore, associated with a favourable benefit-risk ratio compared with some other antidepressant agents. These advantages, seem to be associated with the drug\'s unique chemistry and pharmacological actions.
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